EYKAPPO (lumasiran) is a prescription medication designed for the treatment of primary hyperoxaluria type 1 (PH1) in pediatric and adult patients. PH1 is a rare genetic disorder characterized by the excessive production of oxalate, a substance that can lead to kidney stones and kidney failure. EYKAPPO works by inhibiting the production of glycolate oxidase, an enzyme involved in the production of oxalate, thereby reducing oxalate levels in the body. This medication is administered through subcutaneous injection and has been shown to significantly decrease oxalate levels, potentially mitigating the risk of kidney damage and improving patient outcomes. As with any medication, it is important to use EYKAPPO under the guidance of a healthcare professional to ensure its safety and effectiveness.